• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by SomaLogic Inc. (Amendment)

    1/9/24 5:16:22 PM ET
    $SLGC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SLGC alert in real time by email
    SC 13D/A 1 d10932118_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    SomaLogic, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    83444K105
    (CUSIP Number)

     

    CMLS Holdings II LLC

    Eli Casdin and Keith Meister

    c/o Corvex Management LP

    667 Madison Avenue

    New York, New York 10065

     

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    January 5, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d 1(e), 240.13d-1(f) or 240.13d 1(g), check the following box [  ].

    _______

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      CMLS Holdings II LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      C-LSH II LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      M-LSH II LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Capital, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA  
         

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners Master Fund, L.P.  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  
         

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners GP, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  
         

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Eli Casdin  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, IN  
         

     

     
     

     

    CUSIP No. 83444K105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Keith A. Meister  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      0  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      0  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      0  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      0%  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, IN  
         

     

     

     
     

     

     

    CUSIP No. 83444K105    

     

    Item 1. Security and Issuer.  

     

      The name of the issuer is SomaLogic, Inc., a Delaware corporation (the "Issuer").  The address of the Issuer's principal executive offices is 2945 Wilderness Place, Boulder, CO 80301.  This Schedule 13D amendment relates to the Issuer's Common Stock, $0.0001 par value per share (the "Shares").  
         
         

     

     

    Item 2. Identity and Background.  

     

      (a), (f) This Schedule 13D is being filed jointly by CMLS Holdings II LLC, a Delaware limited liability company ("CMLS"), C-LSH II LLC, a Delaware limited liability company (“C-LSH”), M-LSH II LLC, a Delaware limited liability company (“M-LSH”), Casdin Capital, LLC, a Delaware limited liability company (“Casdin”), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), Casdin Partners GP, LLC, a Delaware limited liability company (the “GP”), Eli Casdin, a United States citizen and Keith A. Meister, a United States citizen (collectively, the "Reporting Persons").    
           
      (b) The principal business address for each of CMLS, C-LSH, M-LSH and Keith A. Meister is 667 Madison Avenue, New York, New York 10065 and the principal business address for each of Casdin, the Fund, the GP and Eli Casdin is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.  
           
      (c) The Board of Managers of CMLS is comprised of Eli Casdin and Keith A. Meister.  C-LSH and M-LSH are the members of CMLS Holdings II LLC and Eli Casdin and Keith A Meister are the managing members of C-LSH and M-LSH. Eli Casdin is the managing member of Casdin and the GP.  The principal business of Casdin is serving as an investment adviser to its clients.  The principal business of the GP is serving as the general partner to certain private funds.  Casdin is the investment manager to the Fund and the GP is the general partner of the Fund.  The principal business of the Fund is purchasing, holding and selling securities for investment purposes.  
           
      (d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.  The Reporting Persons disclaim membership in a group.    

           
         

     

     

    Item 3. Source and Amount of Funds or Other Consideration.  
         
      The funds for the purchase of the Shares came from the working capital of CMLS Holdings II LLC and from private investment funds managed by Casdin, including the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion.  No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.      
         

     

     
     

     

    Item 4. Purpose of Transaction.  
         
     

    The Issuer entered into an Agreement and Plan of Merger on October 4, 2023 (the “Merger Agreement”) with Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Standard BioTools (“Merger Sub”). The Issuer’s stockholders adopted the Merger Agreement at a special meeting of stockholders held on January 4, 2024 (the “Special Meeting”). Pursuant to the terms of the Merger Agreement, on January 5, 2024, following the filing of a certificate of merger with the Secretary of the State of Delaware, Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Standard BioTools (the “Merger”).

     

    Pursuant to the terms of the Merger Agreement, upon completion of the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger was converted into the right to receive 1.11 (the “Exchange Ratio”) fully paid and non-assessable shares of common stock, par value $0.001 per share, of Standard BioTools (the “Standard BioTools Common Stock”), and cash in lieu of any fractional shares.

     

    In addition, as of the effective time of the Merger, Standard BioTools assumed each Issuer stock incentive plan, each outstanding option to Shares (the “Options”) and each outstanding restricted stock unit convertible into Shares (“RSUs,” and together with the Options, the “Equity Awards”), whether vested or unvested. Each such Equity Award assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Equity Award immediately prior to the effective time of the Merger, except that (A) such Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of Shares subject to such Option immediately prior to the effective time of the Merger multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, (B) the exercise price per share will be the exercise price per share in effect for that Option immediately prior to the effective time of the Merger divided by the Exchange Ratio and rounded up to the next nearest cent and (C) such RSU will vest for that number of shares Standard BioTools Common Stock equal to the number of Shares subject to such RSU immediately prior to the effective time of the Merger multiplied by the Exchange Ratio and rounded to the next nearest share of Standard BioTools Common Stock.

     

    In addition, as of the effective time of the Merger, each Issuer warrant (“Warrants”) shall be treated in accordance with the terms of such warrant.

     

    The foregoing description of the Merger Agreement and the transactions contemplated thereby is qualified in its entirety by reference to the Merger Agreement, a copy of which is incorporated herein by reference to Exhibit 2.1 of the 8-K filed by the Issuer on January 5, 2024.

     

     
         

     

    Item 5. Interest in Securities of the Issuer.  
         
     

    As of the Merger, the Reporting Persons were no longer deemed to beneficially own any Shares.

     

    The Reporting Persons have not effected any transactions in the Issuer’s Shares during the past 60 days other than as described herein.

     

    No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares beneficially owned by the Reporting Persons.

     
         

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  
         
      Not applicable.  
         

     

    Item 7. Material to be Filed as Exhibits.  

     

     

    Exhibit A: Joint Filing Agreement

    Exhibit B: Schedule of Transactions in Shares

         

     

     
     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

        January 9, 2024  
        (Date)  

     

     

    CMLS Holdings II LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Manager
      (Name/Title)
       
     

    C-LSH II LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
     

    M-LSH II LLC*

     

    By: /s/ Keith A. Meister

      (Signature)
       
      Keith A. Meister, Managing Member
      (Name/Title)
       
     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)

     

       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
     

    Eli Casdin

     

      /s/ Keith A. Meister*
     

    Keith A. Meister

     

     

     

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 10001).

     
     

     

     

    Exhibit A

     

     

    AGREEMENT

     

     

    The undersigned agree that this Schedule 13D amendment, dated January 9, 2024, relating to the Common Stock, $0.0001 par value per share, of SomaLogic, Inc. shall be filed on behalf of the undersigned.

     

        January 9, 2024  
        (Date)  

     

     

    CMLS Holdings II LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Manager
      (Name/Title)
       
     

    C-LSH II LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
     

    M-LSH II LLC

     

    By: /s/ Keith A. Meister

      (Signature)
       
      Keith A. Meister, Managing Member
      (Name/Title)
       
     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
     

    Eli Casdin

     

      /s/ Keith A. Meister
     

    Keith A. Meister

     

     

     

     

     

    Get the next $SLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGC

    DatePrice TargetRatingAnalyst
    10/5/2023$3.50 → $2.29Buy → Hold
    Jefferies
    9/25/2023$5.00 → $2.50Buy → Hold
    Canaccord Genuity
    2/1/2022$12.00Buy
    Stifel
    12/14/2021$19.00Buy
    Canaccord Genuity
    12/10/2021$16.00Buy
    Jefferies
    11/23/2021$18.00Outperform
    Cowen & Co.
    More analyst ratings

    $SLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

      Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi

      3/5/24 4:35:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Standard BioTools Stockholders Approve Merger with SomaLogic

      SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be

      1/4/24 10:23:06 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

      Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor

      1/4/24 9:44:00 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 5:25:49 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 4:00:59 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by SomaLogic Inc. (Amendment)

      SC 13D/A - SomaLogic, Inc. (0001837412) (Subject)

      1/9/24 5:16:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Financials

    Live finance-specific insights

    See more
    • SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

      Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders. The full text of the letter is as follows: Dear Fellow Stockholders, We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockhold

      12/29/23 8:42:00 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ISS Recommends SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

      BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. In its "FOR" recommendation to SomaLogic stockholders, ISS noted1: The strategic rationale of combining two sub-scale companies in order to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the two companies' offerings and the estimated synergies in this transaction.…the all-sto

      12/22/23 6:47:52 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

      Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote "FOR" Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (NASDAQ:LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on th

      12/21/23 8:00:00 AM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:54:27 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Ryan Jason

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:53:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:52:15 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SomaLogic downgraded by Jefferies with a new price target

      Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously

      10/5/23 7:49:23 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded SomaLogic from Buy to Hold and set a new price target of $2.50 from $5.00 previously

      9/25/23 9:02:13 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on SomaLogic with a new price target

      Stifel initiated coverage of SomaLogic with a rating of Buy and set a new price target of $12.00

      2/1/22 6:15:39 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SomaLogic Announces Chief Financial Officer Transition

      Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti

      6/6/23 4:05:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

      BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill

      10/17/22 4:30:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    SEC Filings

    See more
    • SEC Form 15-12G filed by SomaLogic Inc.

      15-12G - SomaLogic, Inc. (0001837412) (Filer)

      1/16/24 8:00:29 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:06 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:08 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care